SULFASALAZINE vs Vedolizumab

Compare SULFASALAZINE (Sulfasalazine) and Vedolizumab (Entyvio) — clinical data, side effects, and patient experiences.

SULFASALAZINE

Sulfasalazine · Aminosalicylate (IBD)

How it works

Other agent

Approved for

INDICATIONS AND USAGE Sulfasalazine Tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis

and as adjunctive therapy in severe ulcerative colitis

and b) for the prolongation of the remission period between acute attacks of ulcerative colitis.

OralTablet

Vedolizumab

Entyvio · Integrin Inhibitor

How it works

Humanized monoclonal antibody that binds alpha4-beta7 integrin, blocking lymphocyte trafficking to gut-associated lymphoid tissue.

Approved for

Ulcerative Colitis

Crohn's Disease

FDA: 2014Intravenous, SubcutaneousInjection

Quick Comparison

SULFASALAZINEVedolizumab

Drug Class

Aminosalicylate (IBD)

Integrin Inhibitor

Route

Oral

Intravenous, Subcutaneous

Half-Life

—

FDA Approved

—

2014

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

SULFASALAZINE

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Condition Worsened

0.1-1%

Hair Loss

0.1-1%

Vedolizumab

Drug Not Working

1-10%

Diarrhea

1-10%

Abdominal Pain

1-10%

Fatigue

1-10%

Joint Pain

0.1-1%

General Unwellness

0.1-1%

Nausea

0.1-1%

Headache

0.1-1%

FDA Warnings

SULFASALAZINE

WARNINGS Hepatic, Renal, and Hematologic Toxicity or Other Conditions Only after critical appraisal should Sulfasalazine Tablets be given to patients with hepatic or renal damage or blood dyscrasias
Deaths associated with the administration of sulfasalazine have been reported from hypersensitivity reactions, agranulocytosis, aplastic anemia, other blood dyscrasias, renal and liver damage, irreversible neuromuscular and central nervous system changes, and fibrosing alveolitis
The presence of clinical signs such as sore throat, fever, pallor, purpura, or jaundice may be indications of serious blood disorders or hepatotoxicity
Serious Infections Serious infections, including fatal sepsis and pneumonia, have been reported

Vedolizumab

PML risk (rare)
Infections
Liver injury

Clinical Trial Data

No head-to-head clinical studies found for SULFASALAZINE vs Vedolizumab.

SULFASALAZINE vs Vedolizumab: What You Should Know

Key Differences

SULFASALAZINE is a Aminosalicylate (IBD), while Vedolizumab belongs to the Integrin Inhibitor class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles. SULFASALAZINE is administered via Oral, whereas Vedolizumab uses Intravenous or Subcutaneous. Route of administration can affect onset of action and patient adherence.

Safety Considerations

SULFASALAZINE carries 4 FDA warnings. Vedolizumab carries 3 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

BALSALAZIDE DISODIUM vs SULFASALAZINE→MESALAMINE vs SULFASALAZINE→ADALIMUMAB vs SULFASALAZINE→SULFASALAZINE vs USTEKINUMAB→AZATHIOPRINE vs SULFASALAZINE→METHOTREXATE vs SULFASALAZINE→

Loading comparison data...

SULFASALAZINE vs Vedolizumab

Compare SULFASALAZINE (Sulfasalazine) and Vedolizumab (Entyvio) — clinical data, side effects, and patient experiences.

SULFASALAZINE

Sulfasalazine · Aminosalicylate (IBD)

How it works

Other agent

Approved for

INDICATIONS AND USAGE Sulfasalazine Tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis

and as adjunctive therapy in severe ulcerative colitis

and b) for the prolongation of the remission period between acute attacks of ulcerative colitis.

OralTablet

Vedolizumab

Entyvio · Integrin Inhibitor

How it works

Humanized monoclonal antibody that binds alpha4-beta7 integrin, blocking lymphocyte trafficking to gut-associated lymphoid tissue.

Approved for

Ulcerative Colitis

Crohn's Disease

FDA: 2014Intravenous, SubcutaneousInjection

Quick Comparison

SULFASALAZINEVedolizumab

Drug Class

Aminosalicylate (IBD)

Integrin Inhibitor

Route

Oral

Intravenous, Subcutaneous

Half-Life

—

FDA Approved

—

2014

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

SULFASALAZINE

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Condition Worsened

0.1-1%

Hair Loss

0.1-1%

Vedolizumab

Drug Not Working

1-10%

Diarrhea

1-10%

Abdominal Pain

1-10%

Fatigue

1-10%

Joint Pain

0.1-1%

General Unwellness

0.1-1%

Nausea

0.1-1%

Headache

0.1-1%

FDA Warnings

SULFASALAZINE

WARNINGS Hepatic, Renal, and Hematologic Toxicity or Other Conditions Only after critical appraisal should Sulfasalazine Tablets be given to patients with hepatic or renal damage or blood dyscrasias
Deaths associated with the administration of sulfasalazine have been reported from hypersensitivity reactions, agranulocytosis, aplastic anemia, other blood dyscrasias, renal and liver damage, irreversible neuromuscular and central nervous system changes, and fibrosing alveolitis
The presence of clinical signs such as sore throat, fever, pallor, purpura, or jaundice may be indications of serious blood disorders or hepatotoxicity
Serious Infections Serious infections, including fatal sepsis and pneumonia, have been reported

Vedolizumab

PML risk (rare)
Infections
Liver injury

Clinical Trial Data

No head-to-head clinical studies found for SULFASALAZINE vs Vedolizumab.

SULFASALAZINE vs Vedolizumab: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.